[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Montpellier\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":699},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,188,0,25,[9,44,74,110,142,169,196,224,252,282,307,331,358,382,403,427,453,484,513,541,566,592,618,646,669],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100538206","french-assessment-of-mrd-by-liquid-biopsies-in-stage-iii-crc-patients-frenchmrdcrc-100538206",false,"NCT06287814","French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Stage III Colorectal Patients","FRENCH.MRD.CRC PART I Inclusion criteria\n\n* Colon or rectal cancer, clinical tumor stage I-III.\n* Patient 18 years or older.\n* Scheduled for curative intent resection surgery (including \"compromised\" curative resections).\n\nExclusion criteria\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Verified distant metastases.\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.\n\nFRENCH.MRD.CRC PART II Inclusion criteria\n\n* Participation in FRENCH.MRD.CRC part 1 - SURGERY\n* Colorectal cancer, UICC stage III\n* Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime) Exclusion criteria\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer\n* Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included)\n* Treated with neoadjuvant chemo-radiation therapy\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH-MRD-CRC is the French study of the european GUIDE.MRD project.",[25,26,27,28],"Colorectal Cancer","Stage III Colon Cancer","Minimal Residual Disease","Liquid Biopsy",[30,27,28],"Stage III colorectal cancer","RECRUITING","2026-08-14",{"date":34,"type":35},"2026-08-18","ACTUAL",{"date":37,"type":35},"2024-04-11",{"date":39,"type":21},"2033-10-31",{"name":41,"class":42},"University Hospital, Montpellier","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":7},"100649571","phase-3-acetazolamide-in-patients-with-heart-failure-to-decrease-weight-and-relieve-symptoms-100649571","NCT07737964","ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.","ACHIEVE","Inclusion Criteria:\n\n* Age ≥ 18\n* Known HF with impaired, midly-reduced or preserved LVEF\n* Under guideline directed medical therapy for HF according to ESC Heart Failure Guidelines applicable at inclusion\n* Previously followed (or included at hospital discharge) by remote monitoring allowing daily weight by connected scale (i.e. Careline®, Optified-self®, NewCard®, Implicity®)\n* Under furosemide diuretic treatment ≥ 20mg\u002Fday for at least 30 days prior to inclusion\n* Current unplanned hospitalization or unplanned\u002Femergent consultation for acute\u002Fdecompensation HF\n\nExclusion Criteria:\n\n* Subject unable to express their consent and sign informed consent form\n* Subject not covered by public health insurance\n* Refusal to participate (absence of informed consent).\n* Subject under guardianship, legal protection, or deprived of liberty.\n* Pregnant or breastfeeding women.\n* Subject under law protection and prisoners\n* Women of child bearing potential, unless they are using an effective method of birth control (i.e. oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner)\n* Subject unable to comprehend or adhere to the protocol and follow-up\n* Concurrent participation in another interventional study.\n* Chronic ventricular assist device or heart transplant patients.\n* Acute heart failure from recent acute coronary syndrome (\\\u003C 1 month).\n* Severe chronic renal failure or dialysis (GFR \\\u003C 20 ml\u002Fmin).\n* History of renal colic, hyperchloremic acidosis and wheat allergy (other than coeliac disease)\n* Known severe hepatic insufficiency defined by a PTT \\\u003C 50% or a Child-Pugh score C and\u002For a known (clinial or biological) supplemented adrenal insufficiency\n* Intolerance to sulphonamides\n* Hypersensitivity to the active substance (Acetazolamide) or to any of the excipients (Calcium carbonate, wheat starch, gelatine, magnesium stearate)\n* Concomitant use of carbamazepine or quinidinics (hydroquinidine, quinidine)\n* Low cardiac output syndrome\u002Fcardiogenic shock.\n* Current use of acetazolamide or any other carbonic anhydrase inhibitor, including but not limited to topical ophthalmic formulations (e.g., brinzolamide, dorzolamide, methazolamide)\n* Concomitant use of lithium, valproic acid and valpromide\n* Current use of high-dose aspirin (\\>300 mg\u002Fday).\n\nNon-randomization criteria (Criteria should be controlled before patients' randomization) :\n\n* False alarm\n* Time between alarm and randomization \\> 48h\n* Subject who declines his participation\n* Loss of study treatments or unable to take it at D0\n* Hemodynamic instability justifying an urgent hospitalization\n* If applicable, positive urine pregnancy test",{"count":52,"type":21},366,"INTERVENTIONAL",[55],"PHASE3","Acute congestion is common in patients with heart failure (HF) and is associated with impaired renal function, reduced quality of life, hospital readmissions, and mortality. Current guidelines recommend optimal decongestion using diuretic therapy, mainly loop diuretics. Although acetazolamide has recently demonstrated efficacy in hospitalized patients, its role in ambulatory patients managed through remote telemonitoring remains to be established. This study aims to evaluate the efficacy of oral acetazolamide added to conventional treatment for decongesting ambulatory HF patients during congestive decompensations.\n\nACHIEVE is a Phase III multicenter, prospective, interventional, randomized, controlled, open-label superiority trial evaluating the efficacy of oral acetazolamide added to conventional treatment for decongestion in ambulatory patients with heart failure during congestive decompensation monitored by remote telemonitoring.\n\nThe primary objective is to assess, at Day 5, whether acetazolamide added to conventional treatment improves decongestion compared with standard treatment alone. Secondary objectives include evaluating efficacy, safety, and health economic outcomes, including quality of life, dyspnea, biological markers, unplanned consultations, hospitalizations, mortality, and hospital medical costs.",[58],"Heart Failure",[60,61,62,63,64],"heart failure","congestion","ambulatory treatment","remote telemonitoring","diuretics","NOT_YET_RECRUITING","2026-08-13",{"date":68,"type":35},"2026-08-17",{"date":70,"type":21},"2026-10",{"date":72,"type":21},"2029-01",{"name":41,"class":42},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":53,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":43},"100651775","hypersomnia-in-the-paediatric-population-100651775","NCT07766343","Hypersomnia in the Paediatric Population","Hypersomnolence in the Paediatric Population: From Symptom to Pathology, From Screening in the General Population to Phenotyping in Specialist Centres.","SOMNO-PED","Inclusion Criteria:\n\n* For all participants :\n* Be aged between 6 and 17 (\\\u003C 18 years old).\n* Be able to express consent to participate.\n* Have at least one legal guardian.\n* Speak and understand French.\n* Obtain consent from the person(s) with parental authority (or from one parent if the patient is accompanied by only one parent, in accordance with Article 1122-2 of the Public Health Code) or from the child's legal guardian.\n* Be affiliated with a Social Security scheme or be covered by such a scheme\n\nFor patients with CHD :\n\n\\- Patients with a clinical diagnosis of NT1 according to international criteria (32) with symptom onset (sleepiness and\u002For cataplexy) dating back no more than two years. The ICSD-3-TR criteria are: SDE lasting at least 3 months, and the presence of one or two of the following:\n\n1. Well-defined cataplexy, with either:\n\n   * Mean sleep latency of 8 minutes or less on TILEs, and at least 2 episodes of REM sleep onset polysomnography (SOREMP), Or\n   * One episode of SOREMP within 15 minutes of falling asleep during the night of recording.\n2. A hypocretin level in the CSF of less than or equal to 110 pg\u002FmL. OR\n\n   * Patients with a clinical diagnosis of NT2 according to international criteria (30) with onset of sleepiness dating back no more than two years. The ICSD-3 criteria are: SDE evolving for at least 3 years, absence of cataplexy and average sleep latency less than or equal to 8 minutes on TILEs, and at least 2 SOREMPs (one SOREMP the previous night can replace one SOREMP on the TILE). The hypocretin level in the CSF must be greater than 110 pg\u002FmL. In addition, the symptoms and TILE results must not be better explained by other causes (e.g., sleep deprivation, CRD, OSA).\n   * OR\n   * Patients with a clinical diagnosis of IH according to the ICSD-3-TR international criteria, which are as follows: EDS occurring daily for at least 3 months, absence of cataplexy, PSG and MSLT results must not be compatible with narcolepsy (NT1 or NT2): there must be fewer than 2 SOREMPs in total on MSLTs or no SOREMPs if the REM sleep latency on PSG was ≤15 minutes. Also, the presence of at least one of the following two criteria:\n\n\u003C!-- -->\n\n1. Mean sleep latency (TILE) ≤ 8 minutes,\n2. Total sleep time over 24 hours ≥ 12 hours (or over 32 hours ≥ 19 hours) or measured by continuous 24-hour PSG after ensuring that the patient is not sleep deprived (by actigraphy + sleep diary over at least 7 days of unrestricted sleep).\n3. the symptoms of RLS and TILE results must not be better explained by another sleep disorder, medical disorder, psychiatric disorder, or the use of sedative substances or medications.\n\n   For patients with CRD :\n\n   -Patients diagnosed with circadian rhythm sleep disorder (CRD) according to ICSD-3-TR, followed up in secondary\u002Ftertiary care, with symptoms present for ≥3 months. ICSD-3-TR criteria: Sleeping and waking times consistently delayed by ≥2 hours relative to social schedules (e.g., late bedtime with late wake-up time).\n\n   \\- Symptoms have been present for at least three months.\n\n   \\- When patients are allowed to choose their schedule ad libitum, they show an improvement in sleep quality and duration for their age and maintain a delayed phase of the 24-hour sleep-wake pattern.\n   * Confirmation by sleep diaries or actigraphy over ≥7 days.\n   * Absence of comorbidities that primarily alter the circadian rhythm (e.g., narcolepsy, unstable psychiatric disorders, substance use).\n\n   For patients with OSA :\n\n   \\- Patients diagnosed with OSA according to ICSD-3-TR, based on polysomnography at a university hospital or specialized center, with at least:\n   * Apnea + hypopnea index ≥ 1 event\u002Fhour in patients under 18 years of age,\n   * Plus an associated symptom (snoring, breathing difficulties, daytime sleepiness, or behavioral disorders),\n   * Diagnosis confirmed by a second examination if the first is inconclusive or in the event of comorbidity (obesity, craniofacial malformations).\n\n   For patients with Non REM parasomnia :\n\n   \\- Children\u002Fadolescents diagnosed according to ICSD-3-TR with NREM parasomnias (sleepwalking or night terrors):\n\n   \\- Recurrent episodes (≥2 in 6 months) typically occurring during N3 sleep, with no memory or dream content,\n\n   \\- Confusion\u002Freduced responsiveness during the episode,\n\n   \\- Possible confirmation by video PSG or parental history combined with a sleep diary.\n\n   For patients with ASD :\n\n   \\- Patients diagnosed with ASD according to DSM-5, confirmed by a multidisciplinary assessment (ADI-R, ADOS-2, ENT-AM) and monitored by a specialized team. Patients must present with phase delay, prolonged insomnia, or severe sleep fragmentation (WASO \\> 60 min, latency \\> 30 min) as confirmed by actimetry.\n\n   For patients with ADHD :\n\n   \\- Children\u002Fadolescents diagnosed with ADHD according to DSM-5, made by an experienced clinician and confirmed by standardized scales (Conners, ADHD-RS). Must present with sleep disturbances (difficulty falling asleep, WASO \\> 30 min, phase delays, etc.), assessed by actimetry or sleep diary, with symptoms established for ≥ 6 months.\n\n   For patients with obesity :\n\n   -Children\u002Fadolescents with obesity, defined as a body mass index (BMI) above the 97th percentile for age and gender, according to reference curves. The diagnosis is made by an experienced clinician based on standardized anthropometric measurements (weight, height, BMI calculation). They may present with associated sleep disorders (fragmentation, snoring, EDS), as determined by actimetry, polysomnography, or standardized questionnaires.\n\n   Exclusion Criteria:\n\n   -Retrait du consentement.\n   * Souhait du mineur d'interrompre l'étude.\n   * Maladie ou condition intercurrente qui interfère avec la poursuite de la participation du sujet à l'étude.\n   * Lors de la visite 2 : si traitement médicamenteux qui agit sur la somnolence ou la vigilance, ou qui n'a pas été stoppé suffisamment tôt.\n   * Décision de l'investigateur.",true,"6 Years","17 Years",{"count":86,"type":21},760,[88],"NA","This is a 36-month, multicentric, cross-sectional study involving a paediatric population aged 6 to 17 years. Three groups will be included:\n\nGroup A: children from the general population with no complaints of sleepiness; Group B: children with a sleep disorder or excessive sleepiness associated with a medical condition (narcolepsy, circadian rhythm sleep disorder (CRSD), non-REM parasomnias, attention deficit disorder with or without hyperactivity (ADHD), autism spectrum disorder (ASD) or obesity); Group C: healthy volunteers with no medical conditions or sleep-related complaints.",[91,92,93],"Wakefulness Disorder","Narcolepsy","Idiopathic Hypersomnia",[95,96,97,98,99,100,101,102],"sleep disorders","sleepiness","pediatric","screening","phenotyping","scales","psychometric measurements","biological collection","2026-08-10",{"date":32,"type":35},{"date":106,"type":21},"2026-09",{"date":108,"type":21},"2029-11",{"name":41,"class":42},{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100649576","developing-a-comprehensive-biomarker-panel-for-monitoring-progression-and-early-detection-in-als-patients-100649576","NCT07737977","Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients","UNZUELUZON ALS","Inclusion Criteria:\n\n* Age greater than 18 years.\n* Male and female patients with ALS diagnosed according to the El Escorial diagnostic criteria.\n* Sporadic or familial ALS cases.\n* Spinal-onset or bulbar-onset ALS cases.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Individuals deprived of liberty (Article L1121-6), including those subject to judicial or administrative decisions or involuntary hospitalization.\n* Adults under legal protection (guardianship, curatorship, or judicial protection measures) (Article L1121-8).\n* Individuals not affiliated with, or not beneficiaries of, a French social security scheme (Article L1121-8-1).\n* Individuals participating in another research study with an ongoing exclusion period (Article L1121-12).",{"count":118,"type":21},200,"Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.",[121],"ALS (Amyotrophic Lateral Sclerosis)",[123,124,125,126,127,128,129,130,131,132],"ALS","Biomarkers","Amyotrophic Lateral Sclerosis","Diagnosis","Prognosis","Disease Progression","Patient Stratification","Blood Biomarkers","Motor Neuron Disease","Neurodegeneration","2026-07-27",{"date":135,"type":35},"2026-07-30",{"date":137,"type":21},"2026-08",{"date":139,"type":21},"2029-08",{"name":41,"class":42},2,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":53,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":43},"100649557","safe-ips---frances-first-hospital-based-platform-for-the-production-of-induced-pluripotent-stem-cells-for-the-regenerative-medicine-of-the-future-100649557","NCT07735559","SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future","SAFE-iPS","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 35 years\n* No medical contraindication to a 54 mL blood sample collection\n* Negative viral serology for:\n\n  * Human Immunodeficiency Virus (HIV)\n  * Hepatitis B Virus (HBV)\n  * Hepatitis C Virus (HCV)\n  * Human T-lymphotropic Virus type 1 (HTLV-1)\n* A participant who agrees to have their anonymized biological samples and cell lines stored in a biological sample collection for other research purposes (including genetic research)\n\nExclusion Criteria:\n\n* Any active medical condition\n* Any ongoingl treatment\n* Subjects who cannot read and\u002For write\n* Inability to ensure participant during the study period\n* Participation in another clinical trial or administration of an off-label medication that could interfere with blood test results.\n* Participation in another research protocol involving biological sampling that limits the number of mL to be collected.\n* Failure to obtain informed consent\n* Not enrolled in a social security program,\n* Subject participating in another research study with an ongoing exclusion period\n* Protected populations under the French Public Health Code (women who are giving birth, breastfeeding, or pregnant; subjects deprived of liberty by judicial or administrative decision; adults under legal protection (under any form of guardianship))","35 Years",{"count":151,"type":21},6,[88],"The objective of the study is to establish the first French hospital-based Good Manufacturing Practice (GMP)-compliant platform for the production of clinical-grade induced pluripotent stem cells (iPSCs) for future regenerative medicine applications.\n\nThe primary objective is to generate, via the SAFE-iPS platform, 4 clinical-grade iPSC lines derived from peripheral blood samples taken from:\n\n* Two healthy male volunteers\n* Two healthy female volunteers\n\nThese 4 iPSC lines will undergo comprehensive quality assessment including:\n\n* Expression of pluripotency markers\n* Genomic stability assessment\n* Absence of residual Sendai viral integration\n* Technical reproducibility assessment\n* Manufacturing efficiency assessment\n* Preliminary medico-economic evaluation This project aims to demonstrate that the SAFE-iPS manufacturing process can be successfully transferred to a hospital Good Manufacturing Practice (GMP) environment and can reproducibly generate clinical-grade iPSC lines meeting international quality standards for future regenerative medicine applications. It also aims to establish the first French public hospital platform dedicated to routine GMP production of clinical-grade iPSCs.",[155,156],"Regenerative Medicine","Induced Pluripotent Stem Cells (iPSC) Production",[158,159,160,161,162],"Induced pluripotent stem cells (iPSCs),","regenerative medicine,","cell therapy","directed differentiation","clinical-grade production (or GMP manufacturing)",{"date":135,"type":35},{"date":165,"type":21},"2026-11",{"date":167,"type":21},"2028-02",{"name":41,"class":42},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":141},"100564316","impact-of-physical-activity-on-immunotherapy-induced-toxicities-in-melanoma-management-100564316","NCT06627595","Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management","APiTOXMM","Inclusion Criteria:\n\n* age 18 years or above\n* ECOG performance status inferior or equal to 3\n* patient with a melanoma confirmed histologically\u002Fpathologically\n* indication for initiating treatment with anti-PD1 immunotherapy or anti-PD1 + anti-CTLA4\n\nExclusion Criteria:\n\n* patient unable to read and\u002For write\n* inability to follow up with the patient during the study period\n* refusal to participate after a reflection period\n* medical contraindication to initiating immunotherapy (active autoimmune disease requiring systemic treatment in the past 2 years, active infection, etc.)\n* not affiliated with a social security system\n* patient under legal protection, guardianship, or curatorship\n* person participating in another study that includes an ongoing exclusion period",{"count":177,"type":21},160,"Management of melanoma is based on primary excision of the tumor. In cases of melanoma with poor prognosis criteria, or when it is locally advanced or metastatic, there is an indication for the implementation of adjuvant therapy, which may, in this context, be immunotherapy.\n\nImmunotherapies are treatments that have revolutionized the prognosis of patients with melanoma. These are therapies that work by stimulating the immune system to enhance the anti-tumor response. Their toxicities are represented by immune-mediated toxicities, similar to true autoimmune diseases.\n\nAdapted physical activity as supportive care in oncology is expanding. From a pathophysiological perspective, physical activity is thought to modulate the immune system (by reducing inflammation, restoring immune surveillance, stimulating anti-tumor responses through the induction of T cell proliferation, modulating the gut microbiota, and influencing tumor microenvironment cells, etc.).\n\nThe modulation of the immune system by physical activity may also allow us to hypothesize a modulation of the toxicities induced by immune checkpoint inhibitors. We wish to study this hypothesis in patients with advanced melanoma who are candidates for immunotherapy.\n\nOriginality and Innovative Aspects:\n\nPhysical activity as supportive care in oncology has developed significantly in recent years. However, adapted physical activity (APA) is currently only offered at one center in France (CHU de Lille).\n\nIn addition to the probable impact on patients\\' quality of life, if we find evidence supporting a reduction in treatment-related toxicities for melanoma through physical activity, it would be even more interesting to introduce APA at the CHU of Montpellier.\n\nPrimary and Secondary Objectives:\n\nPrimary Objective: To analyze the association between the level of physical activity (estimated by the IPAQ questionnaire) at the initiation of immunotherapy and the occurrence of adverse effects at 6 months after starting treatment in adult patients with melanoma.\n\nSecondary Objectives:\n\nAnalyze the association between physical activity level and treatment efficacy of immunotherapy in adult melanoma patients.\n\nDescribe the quarterly evolution of patients\\' general condition through measurement of WHO status and BMI.\n\nAssess the evolution of patients\\' general condition: WHO status and BMI at treatment introduction, after 3 months, and at 6 months of treatment.\n\nStudy the evolution of patients\\' quality of life during their treatment based on their physical activity level, using the QLQ-C30 questionnaire.\n\nPreliminary study:\n\nWe aim to evaluate the correlation between self-reported physical activity by patients and their actual physical activity. To obtain an objective measurement of patients\\' physical activity level, we plan to work with the CARTIGEN platform and offer a small number of included patients (maximum of 50) to wear wrist actimeters for one week before treatment initiation. We will then analyze these data to determine patients\\' baseline physical activity levels and compare them with the data collected via questionnaires.\n\nThis is a prospective cohort study within the context of analytical epidemiological research. It is a bicentric study: CHRU Montpellier - Saint-Eloi Hospital and ICM Val d\\'Aurelle.\n\nUsing the collected data on patients\\' physical activity levels (IPAQ questionnaire), we will compare two groups: patients who experienced immuno-toxicities without physical activity versus those with moderate or high physical activity.\n\nWe will also analyze treatment efficacy in these two groups, patients\\' quality of life, and the evolution of their general condition.\n\nProcedure:\n\nInclusion is planned at day 0 (D0), with physical activity (IPAQ3) and quality of life (QLQ-C30) questionnaires, along with clinical and oncological evaluation.\n\nA follow-up visit at month 3 (M3) will include reassessment of clinical and oncological status, followed by another visit at month 6 (M6) for further clinical, oncological, physical activity, and quality of life reassessment.\n\nThe inclusion period is expected to last 18 months.\n\nOutcomes \u002F Perspectives:\n\nIf we consider that physical exercise may help mitigate the toxic effects of treatments-an aspect we wish to explore through this project-it would be relevant to introduce adapted physical activity (APA) sessions supervised by a specialized instructor within the Dermatology Day Hospital at the CHU of Montpellier.\n\nImplementing APA in the context of onco-dermatology will strengthen the multidisciplinary approach of the CHU.\n\nCollaboration between healthcare professionals, including specialized APA instructors, will foster effective care coordination.\n\nThis initiative is part of a holistic approach to patient care, integrating complementary interventions to address physical, psychological, and social needs.",[180,181],"Melanoma","Immunotoxicity",[183,184,185,186,187,188],"physical activity","melanoma","immunotherapy","anti-PD-1","anti-CTLA4","immunotoxicity",{"date":190,"type":35},"2026-07-28",{"date":192,"type":35},"2024-11-05",{"date":194,"type":21},"2028-05-05",{"name":41,"class":42},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100647262","serum-neurofilaments-in-the-diagnosis-of-amyotrophic-lateral-sclerosis-100647262","NCT07706270","Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral Sclerosis","Diagnostic Performance of Serum Neurofilaments in the Differential Diagnosis of Amyotrophic Lateral Sclerosis","DIAGONALS","Inclusion Criteria:\n\n* Be at least 18 years of age\n* Be able to undergo blood sampling (however, blood sampling is part of the standard examination and will not be performed exclusively for this study).\n* Patients with suspected ALS\n\nExclusion Criteria:\n\n-• Patients with recent stroke\n\n* Pregnant or breast-feeding women\n* Patient deprived of liberty by judicial or administrative decision, or hospitalization under duress\n* Adult protected by law (guardianship, curatorship)\n* Patient unable to understand and read information and consent forms in French\n* Person participating in another research study with an exclusion period still in progress.\n* Failure to obtain written informed consent after a period of reflection\n* Not affiliated to a social security scheme or beneficiary of such a scheme\n* Person unable to give consent",{"count":205,"type":21},138,"Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease, often difficult to diagnose due to symptoms similar to other neurological pathologies. Diagnosis can take up to 14 months, although the rapid progression of the disease requires early detection. At present, there is no validated biomarker to aid diagnosis. Serum neurofilaments light chain (NfL), markers of neuronal degeneration, show great potential to help diagnose ALS early and assess disease severity. Recent research has shown that measurement of NfL in the blood can differentiate ALS from other neurological disorders, and new technologies are increasingly making it possible to perform these tests clinically.\n\nThe study hypothesis is that NfL blood levels, measured using clinical analyzers, could improve early ALS diagnosis, optimize patient recruitment for therapeutic trials and accelerate the assessment of treatment efficacy.\n\nThe primary objective is to evaluate the sensitivity and specificity of serum NfL for the diagnosis and differential diagnosis of amyotrophic lateral sclerosis (ALS) in newly recruited patients referred to the ALS Reference Center at Montpellier University Hospital. The diagnosis is established according to the revised El Escorial diagnostic criteria (see Appendix). This diagnosis is determined independently of the serum NfL concentration.",[208,209,210],"Amyotrophic Lateral Sclerosis (ALS)","Neurodegenerative Disorders","Motor Neuron Diseases",[212,213,214,215],"amyotrophic lateral sclerosis","neurofilament proteins","glial fibrillary acid protein","early diagnosis","2026-07-16",{"date":218,"type":35},"2026-07-20",{"date":220,"type":21},"2026-08-01",{"date":222,"type":21},"2028-08-01",{"name":41,"class":42},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":232,"maxAge":18,"enrollmentInfo":233,"targetDuration":4,"studyType":53,"phases":235,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":43},"100491626","phase-3-effect-of-sedative-and-anxiolytic-premedication-on-children-experience-after-general-anesthesia-100491626","NCT05681572","Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia","\" Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia \" The pediaPREM Study.","pediaPREM","Inclusion Criteria:\n\n* Subject over 7 and under 18 years of age\n* Subjects who are scheduled for surgery\n* Subject who will be under general anesthesia\n* Subject able to complete a self-questionnaire in French\n\nExclusion Criteria:\n\n* Subject who has already participated in the pediaPREM study\n* Subject with a treated anxiety disorder\n* Subject with cognitive disorders\n* Subject suffering from chronic pain (outside the operated area)\n* Subject with ADD (Attention Deficit Disorder) with or without hyperactivity, with or without treatment\n* Subject suffering from mental retardation\n* Subjects receiving psychotropic treatment\n* Subject whose intervention could reduce the ability to complete a self-questionnaire (neurosurgery etc.)\n* Subject with a contra-indication to midazolam and its excipients\n* Subject with a contra-indication to dexmedetomidine and its excipients\n* Subjects who need to receive intravenous alpha agonist in perioperative\n* Subjects requiring emergency intervention\n* Subjects requiring preoperative hypnosis\n* Subject who needs general anesthesia for diagnostic purposes (biopsy, etc...)\n* Subject having had a surgical intervention in the month preceding the inclusion.\n* Subject who will have an iterative surgical intervention within 15 days (removal of material, burns etc...)\n* Subjects who are scheduled for surgery as part of oncology management\n* Pregnant or breastfeeding woman\n* Subject whose two parents have not signed a written informed consent\n* Subjects who are not affiliated with or benefiting from a social security plan","7 Years",{"count":234,"type":21},1000,[55],"Children undergoing general anesthesia for surgery commonly need sedative and anxiolytic premedication but little clinical evidence supports is benefit for children older than 7 years old.\n\nThe aim of this prospective randomized clinical trial is to assess the impact of pharmacologic premedication on perioperative children experience.",[238],"Anesthesia",[240,241,242,243,244],"children premedication","anesthesia","children perioperative experience","anxiety","sedation",{"date":246,"type":35},"2026-07-17",{"date":248,"type":35},"2023-04-18",{"date":250,"type":21},"2027-10-18",{"name":41,"class":42},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":264,"conditions":265,"keywords":273,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":4},"100647636","comparative-study-of-adherence-to-antibiotic-therapy-among-pediatric-patients-hospital-emergency-department-vs-primary-care-center-100647636","NCT07711756","Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care Center","Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: The Gignac Primary Care Medical Center Versus the Pediatric Emergency Department of Montpellier University Hospital (CHU Montpellier).","ObsATBGignaUrg","Inclusion Criteria:\n\n* Children aged 3 months to 16 years\n* Receiving an outpatient oral antibiotic prescription\n* Diagnosed with an acute bacterial infection\n\nExclusion Criteria:\n\n* Unemancipated minors presenting without a parent or legal guardian.\n* Participation in another clinical research study with an ongoing exclusion period\n* Refusal to participate after the reflection period\n* Parents unable to understand the study information (e.g., language barrier or cognitive impairment)\n* Not affiliated with, or not a beneficiary of, a national health insurance scheme\n* Pregnant or breastfeeding female participants","3 Months","16 Years",{"count":263,"type":21},191,"This study was initiated because of the limited litterature available on this topic. The objective was to compare adherence to antibiotic therapy among a pediatric population treated in two healthcare settings in France: the Gignac Health Center, a primary care facility, and the Pediatric Emergency Department of Montpellier University Hospital. This observational study assessed treatment adherence through a telephone questionnaire administered to parents after the theorical end of the treatment.",[266,267,268,269,270,271,272],"Tonsillitis Acute","Pneumonia - Bacterial","Otitis Media Acute","Cystitis Acute","Sinusitis Bacterial","Pneumonia Atypical","Impetigo",[274],"compliance - antibiotic - pediatric","2026-07-13",{"date":246,"type":35},{"date":278,"type":21},"2026-09-01",{"date":280,"type":21},"2028-09-01",{"name":41,"class":42},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":53,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":43},"100623556","search-for-circulating-tumour-cells-in-the-blood-andor-cerebrospinal-fluid-in-patients-with-recurrent-aggressive-meningiomas-proof-of-concept-study-100623556","NCT07398170","Search for Circulating Tumour Cells in the Blood and\u002For Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study","Search for Circulating Tumour Cells in the Blood and\u002For Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas That Have Recurred: Proof-of-concept Study","BIOLIMEN-1","Inclusion Criteria:\n\n* Over 18 years of age\n* Operated on for a grade 2 or 3 meningioma at Montpellier University Hospital between 2015 and 2024\n* Tumour expressing SSTR2A on the initial surgical specimen\n* Clinical and\u002For radiological recurrence as determined by MRI imaging (progression of a residual lesion OR appearance of a new lesion consistent with a meningioma at the surgical site or elsewhere)\n\nExclusion Criteria:\n\n* Other active ongoing cancer\n* Contraindications to lumbar puncture:\n* Intracranial hypertension with meningioma exerting a mass effect and obstruction of the cerebrospinal fluid (CSF) pathway\u002Frisk of trans-tentorial or amygdalar herniation\n* Blood clotting disorder with risk of haematoma at the puncture site (anticoagulant treatment at therapeutic dose or antiplatelet therapy, thrombocytopenia or thrombopathy)\n* Infection at the puncture site\n* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)\n* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)\n* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)\n* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)\n* Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)\n* Failure to obtain written informed consent",{"count":291,"type":21},15,[88],"The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and\u002For cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.",[295],"Meningioma",[297,298,28,299,300,124],"Meningioma diagnosis","Circulating tumor cells","Neoplasm Recurrence, Local","Therapy",{"date":302,"type":35},"2026-07-14",{"date":275,"type":35},{"date":305,"type":21},"2027-10",{"name":41,"class":42},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":53,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":141},"100531622","risk-prevention-program-and-therapeutic-patient-education-program-of-patients-with-uncontrolled-epilepsy-100531622","NCT06202196","Risk Prevention Program and Therapeutic Patient Education Program of Patients With Uncontrolled Epilepsy","Evaluate the Impact of a Specific Risk Prevention Program Associated With a Therapeutic Patient Education Program on the Risk Behaviors of Adult Patients With Uncontrolled Epilepsy.","EPI-RISK","Inclusion Criteria:\n\n* Patient between 18 and 60 years old\n* Patient with poorly controlled epilepsy (persistence of seizures evolving for more than a year despite proper treatment) or patient seizure-free for over a year but for whom therapeutic patient education (TPE) would be beneficial according to the investigator..\n* Patient agreeing to participate in a therapeutic education program (TPE)\n\nExclusion Criteria:\n\n* Epileptic patient who has already benefited from a TPE epilepsy program\n* Patients with major cognitive impairment\n* Patient under guardianship or legal protection (safeguard of justice)\n* Pregnant or breast-feeding women\n* Failure to obtain written informed consent after a reflection period\n* Patient who for geographical, social or psychological reasons could not participate in the research\n* Any situation that, in the opinion of the investigator, could present risks to the patient and to the research\n* Participation in another therapeutic research\n* Subjects not covered by public health insurance","60 Years",{"count":317,"type":21},74,[88],"Pilot, controled, randomized study aiming to evaluate a plan for the prevention of risks related to epilepsy, 3 months after the last therapeutic patient education session. Two groups of patients will be compared: group \"intervention\" (consultation with the neurologist then a psychologist followed by a session dedicated to risk prevention (\"Recognize and Manage risks\") integrated into usual Therapeutic Patient Education (TPE) versus \"control\" group (usual consultations with the neurologist and usual TPE).\n\n37 subjects per group will be included in this study.",[321],"Epilepsy",[321,323],"Therapeutic Patient Education","2026-07-09",{"date":275,"type":35},{"date":327,"type":35},"2024-04-16",{"date":329,"type":21},"2028-04-16",{"name":41,"class":42},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":53,"phases":340,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":43},"100636761","exploratory-study-of-cerebral-perfusion-and-metabolic-alterations-and-neurocognitive-disorders-in-patients-with-unruptured-arteriovenous-malformations-before-and-after-surgical-treatment-100636761","NCT07569887","Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment","APEMMAV-NR","Inclusion Criteria:\n\n* Adults aged 18 and older\n* Admitted for an unruptured arteriovenous malformation with a decision to proceed with surgery\n\nExclusion Criteria:\n\n* Patients who refuse surgical treatment for arteriovenous malformation\n* Contraindications to 18F-FDG PET (uncontrolled diabete)\n* Patients' inability to lie still for 40 minutes\n* Patients with a confirmed diagnosis of neurodegenerative or psychiatric disorders\n* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)\n* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)\n* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)\n* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)\n* Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)\n* Failure to obtain written informed consent",{"count":339,"type":21},10,[88],"The goal of the clinical trial is to describe perfusion and metabolic alterations in different brain regions before and six months after surgical treatment of arteriovenous malformations in adult patients with unruptured arteriovenous malformations.",[343],"Unruptured Brain Arteriovenous Malformation",[345,346,347,348,349],"Arteriovenous malformation","Perfusion disorders","Metabolism","Positon Emission Tomography","Neuropathology","2026-07-02",{"date":352,"type":35},"2026-07-07",{"date":354,"type":35},"2026-06-16",{"date":356,"type":21},"2028-12",{"name":41,"class":42},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":365,"targetDuration":367,"studyType":22,"phases":4,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":381,"locationsCount":4},"100646945","the-biopsychosocial-model-to-identify-risk-factors-for-chronic-postoperative-pain-in-orthopedic-trauma-surgery-patients-100646945","NCT07685184","The Biopsychosocial Model to Identify Risk Factors for Chronic Postoperative Pain in Orthopedic Trauma Surgery Patients","TRAUMA PAIN","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Surgical treatment for a traumatic fracture\n* Admission to an orthopedic trauma surgery department\n* Ability to participate in follow-up assessments\n* Informed consent\n\nExclusion Criteria:\n\n* Patient unable to exercise consent\n* Patients unable to complete the self reported assessment questionnaires",{"count":366,"type":21},600,"6 Months","This study aims to assess multidimensional risk factors for chronic post-traumatic pain in orthopedic trauma surgery patients. The purpose is to better understand pain chronification mechanisms by quantifying the interaction between clinical, biological, therapeutic, and psychosocial factors during hospitalization, with the ultimate goal of developing a convergent model to predict patients at risk before hospital discharge.",[370],"Post Traumatic Chronic Pain",[372,373,374],"Post traumatic Chronic Pain","Orthopedic Trauma Surgery","Biopsychosocial model","2026-07-01",{"date":377,"type":35},"2026-07-06",{"date":379,"type":21},"2026-07",{"date":356,"type":21},{"name":41,"class":42},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":402,"locationsCount":4},"100646660","prevalence-and-risk-factors-for-chronic-post-surgical-pain-following-video-assisted-thoracic-surgery--the-evatho-prospective-bicentric-cohort-study-100646660","NCT07687082","Prevalence and Risk Factors for Chronic Post-Surgical Pain Following Video-Assisted Thoracic Surgery : The EVATHO Prospective Bicentric Cohort Study.","Study of the Prevalence of Chronic Postoperative Pain After Video-Assisted Thoracic Surgery: A Bicentric Cohort Study","EVATHO","Inclusion Criteria:\n\n* Adult patients undergoing video-assisted thoracic surgery (VATS) for thoracic surgery\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Adults under legal protection or unable to provide informed non-opposition\n* Patients unable to understand or complete the study questionnaires\n* Patients not affiliated with a French health insurance scheme.\n* Adults under legal protection, including judicial safeguard, guardianship, or curatorship.\n* Participation in another clinical study involving an ongoing exclusion period.\n* Pregnant or breastfeeding women.",{"count":391,"type":21},400,"Chronic post-surgical pain (CPSP) remains a common complication after thoracic surgery and may significantly impair patients' quality of life. Although the widespread adoption of video-assisted thoracic surgery (VATS) has reduced surgical trauma and improved postoperative recovery, a substantial proportion of patients still develop persistent pain.\n\nThe EVATHO study is a multicenter prospective observational cohort designed to determine the prevalence of CPSP three months after VATS and to identify perioperative factors associated with its development. Adult patients undergoing thoracic surgery by VATS at Montpellier and Nice University Hospitals will be prospectively enrolled.\n\nPain intensity, neuropathic pain characteristics, anxiety, depression, quality of life, and analgesic consumption will be assessed using validated questionnaires during the perioperative period and at 1 and 3 months after surgery. The results of this study may help identify patients at increased risk of CPSP and improve perioperative pain management strategies following thoracic surgery.",[394,395,396,397],"Chronic Post-surgical Pain","Postoperative Pain After Thoracic Surgery","Neuropathic Pain","Thoracic Surgical Procedures","2026-06-29",{"date":352,"type":35},{"date":220,"type":21},{"date":222,"type":21},{"name":41,"class":42},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":315,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":53,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":424,"leadSponsor":426,"locationsCount":43},"100646978","dialozic---pilot-study-of-a-diagnostic-pathway-for-heart-failure-in-rural-areas-the-contribution-of-telebiology-and-telemedicine-100646978","NCT07682545","DIALOZIC - Pilot Study of a Diagnostic Pathway for Heart Failure in Rural Areas: the Contribution of Telebiology and Telemedicine","DIALOZIC - Pilot Study of a Diagnostic Protocol for Heart Failure in Rural Areas: The Role of Telebiology and Telemedicine","DIALOZIC","Inclusion Criteria:\n\n* Patients over 60 years of age\n* Patient presenting at least 1 sign of EPOF on clinical examination (Shortness of breath at rest or on exertion, orthopnea, nocturnal cough; Rapid weight gain, hepatomegaly ; Peripheral edema ; Fatigue (asthenia), difficulty performing daily activities)\n\nExclusion Criteria:\n\n* Patients covered by Articles L1121-5 through L1121-8 of the Public Health Code (persons under legal protection, guardianship, or conservatorship)\n* Patients not enrolled in the French social security system or an equivalent program\n* Lack of free and informed consent",{"count":412,"type":21},500,[88],"Heart failure is under-diagnosed, even though it is a highly prevalent pathology. The difficulties are accentuated in areas with low medical density. The aim of this project is to demonstrate the value, in terms of diagnosing heart failure, of a Nt-Pro-BNP point of care Test (POCT)in general practices. The aim of this pilot study is to evaluate the reliability of a diagnosis pathway adapted to a low medical density region.",[58,126,416],"Medically Underserved Area",[58,418,419,126,98,420],"NT-proBNP","Telemedicine","rural area","2026-06-26",{"date":377,"type":35},{"date":106,"type":21},{"date":425,"type":21},"2029-03",{"name":41,"class":42},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":436,"conditions":437,"keywords":442,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":43},"100632588","immun4cure-cohort-of-autoimmune-diseases-100632588","NCT07515638","Immun4Cure Cohort of Autoimmune Diseases","Prospective Cohort Study of Clinical and Biological Data in Patients With Autoimmune Diseases (Immun4Cure Cohort)","Immun4Cure","Inclusion Criteria Participants:\n\nGroup 1: RA\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2010\n\nGroup 2: LES\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2019\n\nGroup 3: SSc\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2013\n\nGroup 4: Healthy Controls\n\n* Adults ≥18 years\n* No symptoms of autoimmune disease\n* No first-degree family history of autoimmune disease\n\nExclusion Criteria (all groupes):\n\n* Patients who have refused or are unable to give informed consent\n* Inability to follow the subject during the study period\n* Participation in another interventional study that includes an exclusion period that is still ongoing\n* Pregnant women\n* Not affiliated with a social security scheme\n* Patients without a national insurance number\n* Persons under judicial protection, guardianship or trusteeship\n* Persons deprived of their liberty",{"count":412,"type":21},"This prospective cohort study aims to constitute a 500-participant database and biobank including 450 adults with systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis) and 50 healthy controls.",[438,439,440,441],"Rheumatoid Arthritis","Systemic Lupus Erythematosus","Systemic Sclerosis","Healthy Adult Volunteers",[443,444,445],"Autoimmune disease","multi-omic profiling","immunology",{"date":447,"type":35},"2026-06-30",{"date":449,"type":35},"2026-06-23",{"date":451,"type":21},"2034-06-23",{"name":41,"class":42},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":315,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":53,"phases":463,"briefSummary":465,"conditions":466,"keywords":470,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":43},"100510283","phase-4-daridorexant-to-treat-insomnia-in-patients-with-mild-cognitive-impairment-and-mild-to-moderate-alzheimer-disease-100510283","NCT05924425","Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease","DARIDOR-ALZ","Inclusion criteria :\n\n* Age \\[60-85\\] years old\n* Outpatients\n* Pre-screening:\n\n  * Complaints of dissatisfaction with sleep quantity or quality, despite adequate opportunity for sleep, at least 3 nights per week and for at least 3 months, and\n  * Total sleep time causes clinically significant distress or impairment in daytime functioning, and\n  * Total sleep time estimated by interview was below 6 hours, on at least 3 nights per week and for at least 1 month before screening\n* Baseline PSG (at randomization) assessed TST \\\u003C 6 hours and WASO \\> 1 hour\n* Diagnosis of MCI and AD patients at an early stage according to the NIA diagnosis criteria (core clinical criteria for MCI, positive CSF Aβ42 and\u002For positive plasma biomarker, and neuronal injury (hippocampal and\u002For temporal atrophy by MRI))\n* MMSE from 12 to 26\n* Clinical Dementia Rating CDR from 0.5 to 2\n* Use of CNS-active medications is permitted provided the dose has been stable for at least 3 months, including: anticholinesterase drugs (rivastigmine, donepezil, galantamine) or memantine, antidepressants SSRI (e.g. fluoxetine, sertraline, paroxetine…), SNRI (e.g. venlafaxine, duloxetine), neuroleptics (e.g. clozapine, olanzapine, aripiprazole...) or drug for pain level 2 (codeine, tramadol).\n* For a male subject who is not sterilized and is sexually active with a female partner of childbearing potential, no contraceptive methods are needed\n\nNon inclusion criteria :\n\n* Patients significantly dependent on caregivers\n* Institutionalized patients\n* Analphabetism or subjects unable to read or\u002Fand write\n* Patients unable to perform the neuropsychological tests\n* Patients unable to complete the study instruments (sleep diary)\n* Planned longer stay outside the region that prevents compliance with the visit schedule\n* Patients who cannot be followed up for at least 2 months\n* History of narcolepsy and\u002For cataplexy\n* History of drug or alcohol abuse or addiction\n* History of diagnosed and characterized psychiatric disorders (DSM-5), cured or stabilized (with or without the same treatment for at least 3 months) and excluding any current characterized psychiatric disorder (DSM-5), the diagnosis of which is established by a psychiatrist trained in geriatric psychiatry\n* Moderate and severe liver failure\n* PSG baseline evidence of significant\u002Fsevere sleep-related breathing disorder (defined as \\>30 apnea\u002Fhypopnea episodes per hour)\n* Treatments interfering with sleep-wake patterns\n* Use of hypnotics (benzodiazepines, zolpidem, zopiclone) or drug for pain level 3 (morphine and derivatives)\n* Hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics (SmPC)\n* Forbidden and restricted concomitant medications:\n\n  * Concomitant CNS-depressant medicinal products\n  * CYP3A4 inhibitors\n  * CYP3A4 inducers\n* Participation in another clinical trial or administration of an investigational product\n* Protected population according to articles of the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship\u002Fcuratorship).\n* Subjects not covered by public health insurance\n* Failure to obtain written informed consent after a reflection period","85 Years",{"count":462,"type":21},62,[464],"PHASE4","DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and orexin-2 receptors, in selected populations of MCI and mild-to-moderate AD patients with insomnia complaints.",[467,468,469],"Alzheimer Disease","Insomnia Disorder","Sleep",[471,472,473,474,469,475],"Orexin","Daridorexant","Cognition","Alzheimer","Insomnia","2026-06-24",{"date":478,"type":35},"2026-06-25",{"date":480,"type":35},"2024-03-13",{"date":482,"type":21},"2028-03-13",{"name":41,"class":42},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":491,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":53,"phases":494,"briefSummary":495,"conditions":496,"keywords":499,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":43},"100607497","phase-3-a-prospective-randomized-non-inferiority-trial-comparing-anti-cd20-maintenance-versus-de-escalation-strategy-in-relapsing-remitting-multiple-sclerosis-100607497","NCT07189325","A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","DESIRE MS","Inclusion criteria :\n\n* Patients ≥40 years at inclusion\n* Patients with relapsing remitting multiple sclerosis at inclusion (according to 2017 McDonald criteria) treated with anti-CD20 for at least the last 3 years. For patients treated with IV ocrelizumab or rituximab at extended interval dosing, a maximum interval of 12 months between perfusions during the year before inclusion visit is required.\n* No evidence of disease activity for the last 3 years on anti-CD20 (No relapse AND no new\u002Fenlarged MRI lesion)\n* Brain MRI performed according to OFSEP protocol within a maximum of 6 months before randomization\n\nNon-inclusion criteria :\n\n* Secondary or primary progressive MS at inclusion\n* Previous experience of treatment failure in patients treated with natalizumab, fingolimod, rituximab, ocrelizumab, mitoxantrone, alemtuzumab or cladribine\n* Treatment with high dose corticosteroids during the 30 days preceding inclusion\n* Contraindication to MRI\n* Severely immunocompromised state\n* Current severe active infection\n* Known active malignancy\n* Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease\n* Severe hepatic impairment (Child-Pugh class C)\n* Significantly impaired bone marrow function or significant anaemia, leukopenia, neutropenia or thrombocytopenia\n* Severe renal impairment undergoing dialysis\n* Severe hypoproteinaemia, e.g. in nephrotic syndrome\n* Current severe depression and\u002For suicidal ideation\n* Suspected or confirmed progressive multifocal leukoencephalopathy (PML)\n* Any condition that, in the opinion of the investigator, would interfere with the interpretation of patient safety or place the patient at high risk for treatment-related complications\n* Participation in another therapeutic trial in the last 6 months\n* Protected population according to articles of the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship\u002Fcuratorship)\n* All women of childbearing age not using effective contraception during the study\n* Subjects not covered by public health insurance\n* Failure to obtain written informed consent after a reflection period","40 Years",{"count":493,"type":21},250,[55],"Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit\u002Frisk profiles have been introduced leading to dramatic changes in the prognosis of MS.\n\nFirst, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability.\n\nMore recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis.\n\nAnti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes.\n\nTaking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.",[497,498],"Relapsing-Remitting Multiple Sclerosis (RRMS)","Anti-CD20 Therapy",[500,501,502,503,504,505],"Multiple Sclerosis","High efficacy therapies","de-escalation","adverse events","relapses","escalation","2026-06-22",{"date":449,"type":35},{"date":509,"type":35},"2026-06-15",{"date":511,"type":21},"2031-06",{"name":41,"class":42},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":43},"100644212","efficacy-of-islet-re-transplantation-after-failure-of-beta-cell-replacement-100644212","NCT07666789","Efficacy of Islet Re-transplantation After Failure of Beta-cell Replacement","Efficacy and Safety of Islet Re-transplantation After Failure of Beta-cell Replacement","MULT-ILOT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of type 1 diabetes\n* Prior beta-cell replacement therapy : islet transplantation or pancreas transplantation\n* Islet re-transplantation performed after 2005\n* Islet re-transplantation performed after documented beta cell graft failure, defined by undetectable C-peptide and\u002For recurrence of severe hypoglycemia on insulin therapy\n* Availability of clinical and biological data required for assessment of study outcomes\n\nExclusion Criteria:\n\n* Missing or incomplete data preventing assessment of the primary outcome\n* Patients who did not meet inclusion criteria",{"count":522,"type":21},20,"Islet transplantation and pancreas transplantation are established therapeutic options for selected individuals with type 1 diabetes experiencing severe glycemic instability and recurrent hypoglycemia. Although these approaches significantly improve glycemic management and quality of life, long-term graft survival remains limited, with a progressive decline in beta-cell function over time.\n\nThe clinical benefit-risk profile of islet re-transplantation after graft failure remains poorly defined, and outcomes following repeat islet transplantation after prior islet graft failure have not been specifically evaluated.\n\nRepeated exposure to multiple donors may increase the risk of alloimmunization, including the development of donor-specific antibodies , which may adversely affect graft survival and limit access to future transplantation.\n\nThis multicenter retrospective cohort study aims to evaluate the efficacy and safety of islet re-transplantation in adults with type 1 diabetes after failure of initial beta-cell replacement (islet or pancreas transplantation), with outcomes assessed at 3 months, 1 year, and 5 years.",[525,526],"Type 1 Diabetes (T1D)","Islets of Langerhans Transplantation",[528,529,530,531,532,533],"islet transplantation","pancreas transplantation","type 1 diabetes","beta cell replacement","graft survival","glycemic control","2026-06-21",{"date":476,"type":35},{"date":537,"type":35},"2025-07-31",{"date":539,"type":21},"2026-09-30",{"name":41,"class":42},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":548,"enrollmentInfo":549,"targetDuration":4,"studyType":53,"phases":551,"briefSummary":552,"conditions":553,"keywords":557,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":565,"locationsCount":43},"100618920","conceptualizing-borderline-personality-disorder-as-a-relationship-use-disorder-100618920","NCT07337889","Conceptualizing Borderline Personality Disorder as a Relationship Use Disorder","TLUR","Inclusion Criteria:\n\n* General : aged 18-45\n* Specific :\n* Borderline personality disorder (BPD)assessed by SCID, without bipolar disorder\n* Bipolar disorder (assessed by SCID), without BPD (evaluated by SCID)\n* Healthy controls with no psychiatric disorders (screened by SCID).\n\nExclusion Criteria:\n\n* Psychotic disorders (evaluated by SCID)\n* lack of informed consent\n* Not affiliated with social security\n* Under judicial or administrative confinement or involuntary hospitalization\n* Protected by law (e.g., under guardianship)\n* Pregnancy or breastfeeding\n* Inability to understand, speak, or write in French\n* Inability to understand the study's purpose or methodology\n* Excluded from another study during the exclusion period\n* Participants who have received over €6000 in annual indemnities\n* For Bipolar Participants (without BPD) : Current moderate or severe depressive episode (BDI score \\> 18) or Current hypomanic\u002Fmanic episode (YMRS \\\u003C 12)","45 Years",{"count":550,"type":21},194,[88],"This study aims to explore a novel conceptualization of Borderline Personality Disorder (BPD) as a \"Relationship Use Disorder.\" The research proposes that BPD shares key features with behavioral addictions, specifically addiction to interpersonal relationships. The study builds upon previous findings suggesting that individuals with BPD experience intense emotional dysregulation, including negative self-perception, shame, and a compulsive need for external validation. This addiction to relationships, much like substance use disorders, is thought to contribute significantly to the difficulties faced by these individuals, including interpersonal conflicts, self-destructive behaviors, and emotional instability.\n\nThe study seeks to demonstrate that the relational difficulties central to BPD meet the diagnostic criteria for addiction as defined by the DSM-5. It will also explore how these relational struggles are mediated by dysfunctional self-perception and whether they are linked to behaviors such as compulsive sexual behaviors (CSBD) or suicidal tendencies. Additionally, the research will investigate the relationship between addiction to relationships and neurobiological factors, including endorphin levels, in individuals with BPD compared to those with bipolar disorder and healthy controls. The hypothesis is that individuals with BPD will exhibit higher levels of relationship addiction, with this addiction being tied to their perception of self-worth and emotional experiences in relationships.\n\nThis innovative approach aims to refine the understanding of BPD, reduce stigma, and improve treatment strategies by providing scientific evidence supporting the conceptualization of BPD as a \"Relationship Use Disorder.\"",[554,555,556],"Borderline Personality Disorder","Borderline Personality Disorder (BPD)","Bipolar Disorder (BD)",[558,559],"borderline personality disorder","relationship-use disorder","2026-06-18",{"date":506,"type":35},{"date":563,"type":35},"2026-06-01",{"date":222,"type":21},{"name":41,"class":42},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":82,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":576,"conditions":577,"keywords":580,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":43},"100491653","platform-for-the-prospective-mother-child-study-of-the-determinants-of-neurodevelopmental-disorders-100491653","NCT05681923","Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders","Platform for the Prospective Mother-child Study of the Determinants of Autism Spectrum Disorder and Neurodevelopmental Disorders Neurodevelopmental Disorders","MARIANNE","INCLUSION CRITERIA:\n\nGeneral inclusion criteria (High risk and Low risk cohorts)\n\nMother:\n\n* Be pregnant (single or multiple pregnancy), at least 16 weeks of amenorrhea,\n* Have at least one biological child of 24 months or older,\n* At least 18 years of age\n\nFather:\n\n* Be the biological father of the unborn child,\n* At least 18 years of age\n\nUnborn Child:\n\n\\- Have a woman study participant as mother.\n\nSpecific inclusion criteria for the High risk cohort:\n\n* Autistic sibling: refers to the biological child(ren) of the mother and\u002For father participating in the study and being the parent(s) of the unborn child\n* Be at least 24 months old and less than 18 years old,\n* Have a confirmed diagnosis of Autism Spectrum Disorder based on medical records. If in doubt, the SRS-2 (Social Responsiveness Scale for Adults) and PEDS-DM (Parents' Evaluation of developmental status) questionnaires will be completed. Only children with positive scores on one of these questionnaires will be included after validation of the diagnosis by an expert committee,\n* In case of several children with Autism Spectrum Disorder based in the siblings, only the last born will be included.\n\nRemarks:\n\n* Autism Spectrum Disorder siblings resulting from a medically assisted procreation are eligible provided that part of the genetic heritage is common to that of the mother or father of the unborn child participating in the study.\n* If the father does not live with the mother of the unborn child, his participation is not required and does not preclude the participation of other family members.\n\nEXCLUSION CRITERIA:\n\nGeneral non-inclusion criteria (High risk and Low risk cohorts):\n\nFather and mother:\n\n* Unable to understand French or the study questionnaires\n* Participant on protective measures (guardianship or curatorship) or deprived of liberty by judicial or administrative decision, or subject to a legal protection measure\n* Not affiliated to a social security system\n* Refusal to participate. In the case of consent given for the born and unborn child, the consent must be given by the person(s) with parental authority.\n* Live at a distance from the recruitment center incompatible with follow-up.\n\nSpecific non-inclusion criteria for the Low risk cohort:\n\nMother and\u002For father of unborn child:\n\n\\- Have a biological child with a diagnosis of Autism Spectrum Disorder or other neuro developmental disorder",{"count":575,"type":21},7320,"Neurodevelopmental disorders such as attention deficit disorder with or without hyperactivity, autism spectrum disorder, language and social communication disorder, motor coordination disorder, learning disorder (dyslexia, dyscalculia, dysorthography), intellectual development disorder are frequent and long-lasting developmental difficulties that can be observed in children in various domains. They are often associated and have a significant impact on daily functioning at school and at home.\n\nThe rate of people affected by neurodevelopmental disorders including autism spectrum disorder have increased significantly over the past 20 years. Improved screening only partly explains this evolution.\n\nA genetic predisposition plays an important role in the occurrence of these disorders, however, current scientific data suggest a multifactorial origin. Exposures such as those related to the use of pesticides, air pollution or the presence of endocrine disruptors in our diet could be involved in the genesis of neurodevelopmental disorders, particularly during intrauterine life, a period of great vulnerability.\n\nThe current diagnostic pathways for autism rarely enable the early identification of babies at risk. Without early detection and timely targeted intervention, these children have a poor health outcome and do not reach their full potential.\n\nThe general objective of the MARIANNE cohort is to constitute a French research infrastructure dedicated to research on the biological and environmental determinants of neurodevelopmental disorders including autism.\n\nThis cohort is based on the follow-up of 1200 families with already a child affected by an autism spectrum disorder, which implies a high risk of neurodevelopmental disorders including autism spectrum disorder for the siblings, and of 500 families from the general population with no excess risk of neurodevelopmental disorders. The total number of subjects to be included (mother, father, unborn child and ASD sibling for the HR group) is thus 6300.\n\nThe inclusion of these families will be at the beginning of a new pregnancy and the follow-up will be carried out from the second trimester of pregnancy until the children are 6 years old, the age at which the diagnosis of neurodevelopmental disorders is possible.\n\nBiological, clinical, social and environmental data will be collected at different stages of the follow-up and will be included into a large database.",[578,579],"Autism Spectrum Disorder","Neurodevelopmental Disorders",[581,582,583,584,585],"exposome","child development","genome","risk factors","prenatal cohort",{"date":506,"type":35},{"date":588,"type":35},"2023-04-19",{"date":590,"type":21},"2034-03",{"name":41,"class":42},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":600,"enrollmentInfo":601,"targetDuration":4,"studyType":53,"phases":602,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":617},"100630878","phase-2-phase-iia-trial-of-anti-cd19-car-t-cells-in-systemic-sclerosis-resistant-to-immunosuppressive-therapy-100630878","NCT07493395","Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","SCLEROCAR: A Phase IIa Trial Evaluating the Efficacy of Anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs","SCLEROCAR","Pre-Inclusion criteria:\n\n1. Diagnosis of systemic sclerosis according to ACR\u002FEULAR 2013 classification (15).we include in the critera the fulfilling of 2013 EULAR\u002FACR criteria and specify disease duration (less than 2 years), score\u002Fclinical evidence for active disease :\n2. Severe and resistant to low dose steroids and at least 2 immunosuppressive treatment including csDMARDs (methotrexate, azathioprine, mycophenolate mofetil) and at least one bDMARDs (Tocilizumab)\n3. Early onset (less than 2 years).\n4. Severity \\& progression of disease be defined by :\n\n   1. .mRSS \\>15 with at least one organ involvement (lung: FVC \\\u003C80%, renal involvement, cardiac involvement, Creatinine \\\u003C 1.5 mg\u002Fdl within 6 months).\n   2. mRSS \\\u003C15 and lung fibrosis progression (FVC -10% DLCO -15% within 6 months)\n5. patients with active disease (as defined by EUSTAR ≥2.5) and to patients with a worsening disease despite 6 months of at least 2 immunosuppressive treatments including one DMARDs (methotrexate, azathioprine, mycophenolate mofetil), and one biological DMARD rituximab or tocilizumab.\n6. Estimated survival time \\> 24 weeks\n7. Age: ≥18 ≤64 years old voluntary to participate in the study and sign the informed consent\n8. Adequate organ functions assessed :\n\n   1. serum Creatinine clearance \\> 40ml\u002Fmi\n   2. adequate bone marrow function (Hemoglobin ≥9g\u002FdL ; PMN ≥ 1 G\u002FL ; Platelets ≥ 100 G\u002FL)\n   3. Alanine aminotransferase (ALT) ≤ 3 x ULN and total bilirubin \\\u003C 2.0 mg\u002FdL (34 μmol\u002FL) (or \\\u003C 3.0 mg\u002FdL \\[51 μmol\u002FL\\] for subjects with Gilbert's syndrome)\n   4. Adequate respiratory function: no dyspnea or grade I dyspnea (Common Terminology Criteria for Adverse Events (NCI CTCAE v 5.0) and oxygen saturation \\>\u002F= 92% on room air\n9. Highly effective contraception methods\n\nInclusion criteria:\n\n1. Adequate organ functions assessed:\n\n   1. serum Creatinine clearance \\> 40ml\u002Fmi\n   2. adequate bone marrow function (Hemoglobin ≥9g\u002FdL ; PMN ≥ 1 G\u002FL ; Platelets ≥ 100 G\u002FL)\n   3. Alanine aminotransferase (ALT) ≤ 3 x ULN and total bilirubin \\\u003C 2.0 mg\u002FdL (34 μmol\u002FL) (or \\\u003C 3.0 mg\u002FdL \\[51 μmol\u002FL\\] for subjects with Gilbert's syndrome)\n   4. Adequate respiratory function: no dyspnea or grade I dyspnea (Common Terminology Criteria for Adverse Events (NCI CTCAE v 5.0) and oxygen saturation \\>\u002F= 92% on room air\n2. Adequate venous access for apheresis\n3. Leucapheresis : a wash-out period of 6 weeks for conventional immunosuppressants (i.e. methotrexate, mycophenolate mofetil)\n4. Leucapheresis : at least 12 weeks after biotherapy (i.e. tocilizumab, 6 months for rituximab),\n\nExclusion Criteria:\n\n1. Craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia or cerebrovascular hemorrhagic diseases\n2. ECG showing prolonged QT interval or history of severe heart diseases or FEVG \\\u003C 40%\n3. Lung and \u002F or heart severe dysfunction defined by CVF\\\u003C50% and\u002For DLCO \\\u003C40%\n4. Pulmonary arterial hypertension defined by catheterism (mean AP \\> 25mmHg at rest or \\> 30mmHg after exercise, PAOP \\\u003C 15mmHG)\n5. Clinically significant active, opportunistic, chronic or recurrent infection (including but not limited to: hepatitis B or C virus or HIV) or covid-19 \\\u003C 1 months including active or latent tuberculosis (TB) infection\n6. Contra indication for autologous hematopoietic stem cell transplantation (AHSCT ) or relapsing at least one year after AHSCT\n7. Active hematological or solid neoplasm\n8. Concurrent therapy with systemic steroids (\\>10 mg\u002Fd prednisone equivalent) within 2 weeks prior to inclusion, except inhaled steroids\n9. Methylprednisolone or prednisone (maximum dose 20 mg) instead of immunosuppressive agents\n10. T cell targeting drugs (e.g. mycophenolate mofetil, azathioprine, calcineurin inhibitors) within 6 weeks prior to leukapheresis\n11. Previous adoptive T cell therapy or any gene therapy including CAR T cell therapy\n12. Live vaccines within 6 weeks prior to leukapheresis\n13. Hypersensitivity against any drug or its ingredients\u002Fimpurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory preparative chemotherapy or rescue medication\u002Fsalvage therapies for treatment related toxicities\n14. patients without social security coverage;\n15. patients under guardianship;\n16. Male or female patients seeking to conceive a child\n17. Women of childbearing potential unless they are using a highly effective method of contraception starting from the time of enrolment and for at least 12 months following LD chemotherapy and until clearance of CAR-T cells, and sexually active male participants unwilling to use a condom. Female partners of sexually active male participants must be on a highly effective form of birth control from the time of enrolment and for at least 12 months following LD chemotherapy and until clearance of CAR-T cells.\n18. pregnant or breastfeeding women;\n19. patients with advanced cognitive disorders or any other cause preventing their informed consent;\n20. active, clinically significant CNS pathology : If signs or symptoms exist which present diagnostic uncertainty, neurologist consultation will be obtained to confirm the diagnosis of any neurological condition\n21. any comorbidity, whatever it may be, which may, in the opinion of the investigator, place the patient at additional risk or interfere with the monitoring of the study.\n22. Concurrent participation in any other interventional trial and Contraindication to the lymphodepleting chemotherapy","64 Years",{"count":151,"type":21},[603],"PHASE2","The goal of this clinical trial is to evaluate whether anti-CD19 CAR T-cell therapy can improve disease activity in adults with severe, treatment-resistant systemic sclerosis (SSc). The study will also assess the safety of this therapy and how CAR T-cells behave in the body.\n\nThe main questions are:\n\nDoes CAR T-cell therapy reduce skin thickening and other signs of SSc? What side effects occur after receiving CAR T-cells? How do CAR T-cells expand, persist, and affect B-cells and autoantibodies?\n\nParticipants will:\n\nUndergo leukapheresis Receive short lymphodepleting chemotherapy Receive one infusion of anti-CD19 CAR T-cells Stay in the hospital for about 10 days Attend follow-up visits for 24 months with clinical exams, blood tests, and organ-function assessments\n\nOptional skin or lymph-node biopsies may be performed in participants who consent to these procedures.\n\nThis study aims to provide early evidence on whether CAR T-cell therapy could become a promising treatment option for systemic sclerosis.",[606],"Scleroderma, Systemic",[440,608,609],"Anti-CD19 CAR T-cells","Autologous CAR T-cell therapy","2026-06-17",{"date":506,"type":35},{"date":613,"type":35},"2026-06-11",{"date":615,"type":21},"2028-06-11",{"name":41,"class":42},4,{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":628,"conditions":629,"keywords":632,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":640,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":4},"100624387","prospective-twin-pregnancy-cohort-at-montpellier-university-hospital-100624387","NCT07408973","Prospective Twin Pregnancy Cohort at Montpellier University Hospital","Twin Pregnancy Cohort at Montpellier University Hospital for a Study of the Impact of the Exposome: Pilot Study","COGEM","Mother's inclusion Criteria:\n\n* Patient of legal age (≥ 18 years)\n* Patient pregnant with a twin pregnancy ≥ 25 weeks of gestation\n* Pregnancy initially twin, triplet, or quadruplet, progressing to a twin pregnancy after spontaneous or medical embryo reduction, or after selective termination of pregnancy\n* Delivery planned at Montpellier University Hospital\n\nTwins' inclusion Criteria:\n\n* Twins born in a twin pregnancy ≥ 25 weeks of gestation\n\nMother's exclusion Criteria:\n\n* Pregnant woman with at least one fetus presenting with a chromosomal or genetic abnormality or a polymalformative syndrome, and for whom early postnatal death is anticipated.\n* Planned travel preventing the study from being completed\n* Failure to obtain informed and written consent from the patient for participation in the study and the collection of biological samples\n* Patient unable to read and\u002For write French\n* Patient unable to understand and\u002For speak French\n* Patient not benefiting from a national health insurance scheme\n* Person under legal protection, guardianship or curatorship\n* Person participating in other interventional research study\n\nTwins' exclusion Criteria:\n\n* Mother's absence from or withdrawal from the study\n* Birth in a facility other than Montpellier University Hospital\n* One or two children under guardianship\n* Lack of informed and written consent from legal representatives\n* One of the two fetuses is expected to die\n* Lack of informed and written consent from the prospective parent(s) for participation in the study and the collection of biological samples\n* Parents unable to read and\u002For write French\n* Parents not understanding and\u002For speaking French",{"count":627,"type":21},360,"This prospective observational cohort study aims to investigate the impact of the maternal and early-life exposome on neonatal and early childhood health outcomes in twin pregnancies followed at University Hospital of Montpellier (France). Grounded in the Developmental Origins of Health and Disease (DOHaD) framework, the study focuses on how environmental, biological, and lifestyle exposures during pregnancy and the first year of life influence fetal growth, neonatal health, and early development.\n\nA total of 120 women with monochorionic or dichorionic twin pregnancies and their 240 children will be included. Maternal exposome assessment includes air pollution exposure, lifestyle, diet, medical history, and biological measurements. Neonatal outcomes, including abnormal birth weight, will be evaluated at birth, and children will be followed until one year of age to assess growth, health events, and developmental outcomes. Biological samples collected at different times during the study will allow the assessment of chemical exposures and epigenetic markers. This study aims to generate original French twin pregnancy data and to improve understanding of environmental determinants of early-life health.",[630,631],"Pregnancy","Twin",[633,634,635,636,637,638,639],"Exposome","Air Pollutants","Lead","Diet, Food, and Nutrition","Healthy Lifestyle","Obstetric Labor Complications","Children Health",{"date":560,"type":35},{"date":642,"type":21},"2026-12",{"date":644,"type":21},"2030-12-01",{"name":41,"class":42},{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":53,"phases":656,"briefSummary":657,"conditions":658,"keywords":660,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":665,"startDateStruct":666,"completionDateStruct":667,"leadSponsor":668,"locationsCount":151},"100622064","phase-2-comparing-udca-and-corticosteroids-in-immunotherapy-induced-cholestatic-hepatitis-100622064","NCT07378761","Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis","Efficacy of Ursodeoxycholic Acid Versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial","CHILURSO","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Any type of cancer except hepatocellular or cholangiocarcinoma\n* At least one ICI injection\n* Cholestatic hepatitis Grade CTC-AE 3 or 4\n\nExclusion Criteria:\n\n* Ongoing corticosteroids treatment\n* Other causes of hepatitis\n* Cirrhosis\n* ICI for hepatocellular carcinoma or cholangiocarcinoma\n* Biliary obstruction\n* Medical contraindication to corticosteroids or UDCA\n* Mixed or hepatocellular hepatitis\n* Total bilirubin \\> 1,5 ULN, Prothrombin rate \\\u003C 70%\n* Medical contraindication to MRI or liver biopsy\n* Oher serious side effects requiring corticosteroids\n* Pregnant and breast-feeding patients\n* Patients under articles L1121-5 to 8 of the public health code\n* Lack of informed consent\n* Patients not affiliated with French social security system\n* Patients uncapable of understanding french",{"count":655,"type":21},94,[603],"The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period.\n\nThe trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids.",[659],"Immune-Mediated Cholestasis",[661,662,663,664],"DILI","Immune checkpoint inhibitors","Cancer","Cholestatic hepatitis",{"date":560,"type":35},{"date":642,"type":21},{"date":139,"type":21},{"name":41,"class":42},{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":675,"eligibilityCriteria":676,"healthyVolunteers":82,"sex":677,"minAge":18,"maxAge":678,"enrollmentInfo":679,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":681,"conditions":682,"keywords":685,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":693,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":43},"100595794","understanding-cycles-to-improve-womens-health-100595794","NCT07037082","Understanding Cycles to Improve Women's Health","Understanding Socio-ecological Variation in Menstrual Cycles to Advance Female Health","C-HEALTH","Inclusion Criteria:\n\n* Woman of childbearing age (18-39 years)\n* Woman not using hormonal contraception for at least 6 months\n* Woman with semi-regular menstrual cycles between 21 and 45 days inclusive\n* Woman with no known history of infertility\n* Woman working in the same environment (urban\u002Frural) as her place of residence\n* Knowledge of the dates of periods over the last 3 cycles\n* Woman who has a freezer at -20°C\n\nExclusion Criteria:\n\n* Diagnosis by a physician of one or more of the following comorbidities: Polycystic ovarian syndrome (PCOS), Endometriosis, Adenomyosis, Diabetes or thyroid disease, Hormone-dependent gynecological cancers (breast, endometrium, ovaries), Coagulation diseases (von Willebrand), Chronic liver failure, chronic renal failure, heart disease, autoimmune disease, Autism, Diagnosis and\u002For treatment for a psychiatric illness\n* Chronic exposure to cocaine, amphetamine\u002Fmethamphetamine, morphine or ecstasy within 30 days prior to inclusion\n* Chronic exposure to THC within 7 days prior to inclusion.\n* Person who is not comfortable with self-sampling (hematophobia or other)\n* No access to a smartphone\n* No possibility of wearing a connected ring for at least 60 days 22h\u002F24h\n* Pregnant or breastfeeding woman\n* Woman who gave birth or breastfed in the 2 months before the study\n* Person who moved less than 2 years before the study (does not concern participants who moved in the same environment (rural or urban, less than 20 km)\n* Person unable to read French\n* Failure to obtain informed consent\n* Person not benefiting from a national health insurance scheme\n* Person under legal protection, guardianship or curatorship\n* Person participating in other research involving the human person","FEMALE","39 Years",{"count":680,"type":21},320,"Introduction:\n\nThe C-HEALTH study investigates how environmental and socio-economic conditions affect women's menstrual cycles and reproductive health.\n\nAim:\n\nTo compare progesterone levels during the luteal phase among women from different socio-economic backgrounds living in rural and urban areas in southern France.\n\nMethods:\n\nThis is a prospective observational study involving 320 healthy women of reproductive age.\n\n* Hormones (progesterone, estradiol) will be measured daily in saliva.\n* Inflammation (Protéine C Réactive: CRP) will be measured five times per cycle via blood drops.\n* Participants will wear a smart ring to monitor body temperature and activity.\n* Daily symptoms and lifestyle data will be collected.\n* Environmental exposures (pollution, stress, living conditions) will be assessed and linked to menstrual health outcomes.",[683,684],"Woman of Reproductive Age","Socioeconomic Factors",[686,633,687,688,689,690,691,692],"Menstrual Cycle","Hormones","Inflammation","Rural\u002FUrban","Socioeconomic status","Pollution","Ovulation",{"date":506,"type":35},{"date":695,"type":35},"2025-09-01",{"date":697,"type":21},"2029-07-01",{"name":41,"class":42},""]